- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of February 26
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 26, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 26.
Number 5: The US Patent Trial and Appeal Board has decided that the Saint Regis Mohawk Tribe cannot claim sovereign immunity from inter partes review of Allergan’s patents covering Restasis, and that the proceedings can continue with Allergan as the patent owner.
Number 4: Infliximab has been proposed as a potential combination treatment that could enhance the effects of chemotherapy in patients with colon cancer.
Number 3: The American College of Rheumatology has updated its health policy statements for 2018, and biosimilars featured heavily in the organization’s concerns for the year ahead.
Number 2: Virginia’s House and Senate have passed a new bill that prohibits pharmacy benefit managers from penalizing pharmacists for sharing drug price information with customers.
Number 1: A health economist from Harvard Medical School is warning that, if biosimilars continue their current trajectory, they could fail to deliver on their promise to provide cost savings to the US health system.
Finally, last week, our e-newsletter asked for your thoughts on whether the extrapolation of indications for biosimilars is reasonable.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Targeted Reimbursement Encourages Oncology Biosimilar Use
May 7th 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
